Cancer Biobank Aichi successfully established a hospital-based research resource that collects blood samples and health information from cancer patients at their first visit. According to Gram Research analysis, 85.2% of 34,574 patients approached agreed to participate, with 22,205 providing both blood samples and detailed lifestyle questionnaires. This biobank enables researchers to study what causes cancer and develop better treatments by linking biological samples with patient medical records and lifestyle information.
According to Gram Research analysis, scientists at Aichi Cancer Center in Japan created a special research tool called Cancer Biobank Aichi (CBBA) to help fight cancer. Starting in 2017, they collect blood samples and health information from patients visiting the hospital for the first time. Out of nearly 35,000 people asked to participate, about 85% agreed to share their blood and answer questions about their lifestyle habits like diet, exercise, and smoking. This information helps researchers understand what causes cancer and develop better treatments. The biobank stores these samples carefully at super-cold temperatures and links them with patient medical records, creating a powerful resource for cancer research.
Key Statistics
A 2026 study of Cancer Biobank Aichi found that 85.2% of 34,574 first-visit outpatients agreed to participate by providing blood samples and/or health questionnaires, demonstrating high feasibility of integrating biobanks into routine hospital care.
Cancer Biobank Aichi collected blood samples from 25,105 participants and questionnaire data from 26,570 participants, with 22,205 providing both components, creating a comprehensive resource linking biological samples to lifestyle information for cancer research.
The biobank included 10,075 non-cancer participants as a comparison group among 29,470 total participants, enabling researchers to identify factors that distinguish people who develop cancer from those who don’t.
Blood samples collected at Cancer Biobank Aichi are processed within 2 hours, fractionated into serum, plasma, and buffy coat, and stored at -80°C with continuous monitoring and backup freezer systems to preserve sample quality for long-term research.
The Quick Take
- What they studied: How to set up and run a hospital-based biobank (a storage facility for biological samples) that collects blood and health information from cancer patients at their first visit
- Who participated: 29,470 people who visited Aichi Cancer Center in Japan for the first time between 2017 and the study period, including 10,075 people without cancer who served as a comparison group
- Key finding: 85.2% of patients approached agreed to participate by providing blood samples and/or answering health questionnaires, with 22,205 people providing both types of information
- What it means for you: This biobank creates a valuable resource for researchers to study cancer causes and develop new treatments, though individual participants may benefit indirectly through improved future cancer care rather than immediate personal benefit
The Research Details
Cancer Biobank Aichi (CBBA) is a prospective biobank, meaning researchers collected samples and information from patients going forward in time rather than looking back at past records. When patients came to the hospital for their first visit, they were asked to donate up to 13 milliliters (about one tablespoon) of blood and complete a detailed questionnaire about their lifestyle habits from the past year, including diet, exercise, smoking, and alcohol use. The blood samples were processed within 2 hours and separated into different components (serum, plasma, and buffy coat, the part containing white blood cells and DNA) that were frozen at -80°C (extremely cold) and stored with continuous monitoring.
The researchers also collected detailed health information through a structured questionnaire that asked about physical activity, diet, smoking habits, and use of electronic cigarettes or heat-not-burn tobacco products. Clinical information was updated yearly by connecting the biobank data with the hospital’s cancer registry, which tracks all cancer cases. For approved research projects, scientists could access additional clinical details while protecting patient privacy through data anonymization.
This design is powerful because it captures information at the moment patients first seek care, before their cancer diagnosis or treatment might change their lifestyle habits. The inclusion of 10,075 non-cancer participants provides a comparison group to help researchers understand what factors differ between people who develop cancer and those who don’t.
This research approach matters because it creates a systematic way to collect high-quality biological samples and lifestyle information that researchers can use for many different studies. By embedding the biobank into the normal first-visit process, the researchers achieved a very high participation rate (85.2%), which means the results are more representative of the actual patient population. Having both biological samples (blood) and detailed lifestyle information linked together allows researchers to investigate how specific habits, genes, and environmental factors contribute to cancer development and progression.
The study demonstrates strong quality through its high participation rate (85.2% of those approached), standardized collection procedures (samples processed within 2 hours, stored at consistent temperatures), use of structured questionnaires, and systematic linkage with hospital cancer registry data. The inclusion of both cancer and non-cancer participants strengthens the research potential. The study follows recommended registration standards from Japan’s National Cancer Center, suggesting adherence to established best practices. However, as a descriptive study of biobank infrastructure rather than a clinical trial, it doesn’t test whether specific interventions work, it establishes the foundation for future research.
What the Results Show
Among 34,574 people approached about participating in Cancer Biobank Aichi, 29,470 (85.2%) agreed to participate by providing either blood samples, questionnaire data, or both. This high participation rate indicates strong community support for cancer research. Of the 29,470 participants, 25,105 provided blood samples that could be used for genetic and molecular studies, while 26,570 completed the health questionnaire. Most importantly, 22,205 people provided both blood samples and questionnaire information, creating a complete dataset for comprehensive research.
The biobank successfully collected and processed blood samples from diverse participants, including 10,075 people without cancer who serve as a comparison group. These non-cancer participants are crucial because they help researchers understand what factors distinguish people who develop cancer from those who don’t. The questionnaire captured detailed information about lifestyle factors from the year before each person’s first hospital visit, including physical activity levels, alcohol consumption, smoking status, diet, and use of electronic or heat-not-burn tobacco products.
The infrastructure established includes secure storage of biological samples at -80°C with continuous monitoring and backup freezer systems to prevent sample degradation. DNA extracted from blood cells is stored in ready-to-use aliquots (small portions), making it convenient for future research. Clinical information is automatically updated annually through connection with the hospital’s cancer registry, which tracks diagnoses, treatments, and outcomes using standardized methods recommended by Japan’s National Cancer Center.
The study demonstrates that embedding biobank collection into routine first-visit outpatient care is feasible and achieves high participation rates without disrupting normal clinical workflows. The structured questionnaire successfully captured both traditional lifestyle factors (diet, physical activity, smoking, alcohol) and emerging exposure areas like electronic cigarette use. The linkage between biospecimens, questionnaire data, and clinical registry information creates multiple research opportunities, scientists can study genetic factors, lifestyle-disease relationships, and how different factors interact to influence cancer development and outcomes.
Cancer biobanks have become increasingly important research tools worldwide, but this study demonstrates a particularly efficient model by integrating collection into first-visit outpatient care rather than requiring separate research appointments. The 85.2% participation rate is notably high compared to many biobank studies, likely because participation was offered as part of routine care rather than as a separate research activity. The inclusion of a non-cancer comparison group within the same hospital setting is a strength that allows for more direct comparisons than biobanks that only collect from cancer patients.
As a descriptive study of biobank infrastructure, this research doesn’t test whether specific health interventions or treatments work, it establishes the foundation for future studies. The study is based at a single cancer center in Japan, so results may not represent all populations or healthcare settings. Participation was voluntary, which means people who agreed to participate might differ from those who declined in ways that could affect research results. The questionnaire asked about lifestyle habits from the year before the first visit, which relies on people’s memory and may not be completely accurate. Additionally, the study doesn’t yet report long-term follow-up outcomes or results from actual research projects using the biobank, so the ultimate value of this resource will become clearer as studies using it are completed.
The Bottom Line
Cancer Biobank Aichi represents a well-designed infrastructure for cancer research with strong evidence of feasibility and high participation rates. Healthcare systems and research institutions should consider adopting similar models that integrate biobank collection into routine clinical care, as this approach achieves high participation without disrupting normal workflows. Researchers interested in cancer epidemiology and genetics should explore opportunities to use this biobank for approved research projects. Patients asked to participate in similar biobanks can feel confident that their samples and information contribute to important cancer research, though individual health benefits may be indirect and long-term.
Cancer researchers, epidemiologists, and clinicians interested in understanding cancer causes should care about this biobank’s establishment and potential. Patients with cancer or at risk for cancer may benefit indirectly through improved treatments developed using this research resource. Healthcare administrators considering how to support cancer research should note this model’s success. People asked to participate in similar biobanks can use this study as evidence that well-designed biobanks operate with strong privacy protections and scientific rigor. However, this research is primarily relevant to the scientific and medical community rather than the general public seeking immediate health advice.
The Cancer Biobank Aichi was established in 2017 and has been collecting samples and data since then. Benefits from this biobank will emerge gradually as research projects using the samples are completed, analyzed, and published, typically taking 2-5 years or longer for individual studies. Improvements in cancer treatment and prevention based on discoveries from this biobank may take 5-10 years or more to translate into clinical practice. Participants should understand that their contribution supports long-term research rather than providing immediate personal health benefits.
Frequently Asked Questions
What is a cancer biobank and why do researchers need one?
A cancer biobank is a facility that stores blood samples and health information from patients for research purposes. Researchers use biobanks to study what causes cancer, identify genetic risk factors, and develop new treatments by analyzing samples linked to patient medical records and lifestyle information.
How many people participated in Cancer Biobank Aichi?
Cancer Biobank Aichi enrolled 29,470 participants out of 34,574 people approached, achieving an 85.2% participation rate. This included 10,075 people without cancer who serve as a comparison group for research studies.
Is my privacy protected if I participate in a cancer biobank?
Cancer Biobank Aichi protects privacy through data pseudonymization (removing identifying information) and governance review of research projects. Samples are stored with 2D barcodes rather than names, and clinical data access is restricted to approved researchers under strict privacy protocols.
What lifestyle information does Cancer Biobank Aichi collect?
The biobank collects detailed information about physical activity, alcohol intake, smoking status, diet, and use of electronic or heat-not-burn tobacco products from the year before each patient’s first hospital visit using structured questionnaires.
How long do I have to wait to see benefits from cancer biobank research?
Individual research projects using biobank samples typically take 2-5 years to complete and publish. Improvements in cancer treatment based on biobank discoveries may take 5-10 years or longer to translate into clinical practice available to patients.
Want to Apply This Research?
- Users interested in cancer prevention could track lifestyle factors that the biobank measures: weekly physical activity minutes, daily alcohol intake (drinks per week), smoking status (cigarettes per day or quit date), and dietary patterns (servings of fruits, vegetables, and processed foods daily). This mirrors the biobank’s data collection approach.
- Users could set goals to improve the lifestyle factors associated with cancer risk: increase physical activity to 150 minutes weekly, reduce alcohol to moderate levels (1 drink daily for women, 2 for men), quit smoking or avoid tobacco products, and increase fruit and vegetable intake to 5+ servings daily. Track progress monthly to see improvements.
- Establish a quarterly review of lifestyle metrics to identify trends and areas for improvement. Compare current habits to baseline measurements to quantify progress. Consider annual health check-ups that include cancer screening appropriate for age and risk factors, and share lifestyle data with healthcare providers to inform personalized prevention strategies.
This article describes a research infrastructure study, not a clinical treatment or prevention recommendation. Cancer Biobank Aichi is a research resource for scientists, not a clinical service for individual patients. If you have concerns about cancer risk or symptoms, consult with your healthcare provider. Participation in biobanks is voluntary and should be based on informed consent. This information is for educational purposes and should not replace professional medical advice, diagnosis, or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
